Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GHDX Genomic Health	$63.44	$64.79	$50.77 ▼ $90.18	$2.38B	0.9	1.05 million shs	N/A
HALO Halozyme Therapeutics	$53.87 -0.2%	$57.34	$42.01 ▼ $70.51	$6.64B	1.19	1.63 million shs	815,390 shs
MDGL Madrigal Pharmaceuticals	$284.87 -3.6%	$297.30	$200.63 ▼ $377.46	$6.32B	-1.08	361,015 shs	191,228 shs
RGEN Repligen	$126.19 -1.0%	$128.58	$102.96 ▼ $182.52	$7.08B	1.1	747,491 shs	867,007 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GHDX Genomic Health	0.00%	0.00%	0.00%	0.00%	0.00%
HALO Halozyme Therapeutics	0.00%	-0.50%	+3.77%	-14.25%	+9.05%
MDGL Madrigal Pharmaceuticals	0.00%	+6.23%	+1.58%	-13.69%	+6.48%
RGEN Repligen	0.00%	-0.61%	+0.81%	-16.55%	+1.51%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GHDX Genomic Health	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
HALO Halozyme Therapeutics	4.8721 of 5 stars	3.1	2.0	0.0	4.4	3.0	2.5	4.4
MDGL Madrigal Pharmaceuticals	4.1728 of 5 stars	3.4	1.0	0.0	4.6	2.5	3.3	0.6
RGEN Repligen	4.7846 of 5 stars	4.3	1.0	0.0	4.5	2.9	3.3	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GHDX Genomic Health	0.00	N/A	N/A	N/A
HALO Halozyme Therapeutics	2.17	Hold	$61.90	14.90% Upside
MDGL Madrigal Pharmaceuticals	2.89	Moderate Buy	$420.63	47.66% Upside
RGEN Repligen	2.64	Moderate Buy	$173.25	37.30% Upside

Current Analyst Ratings Breakdown

Latest GHDX, HALO, RGEN, and MDGL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/29/2025	HALO Halozyme Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$72.00
5/14/2025	HALO Halozyme Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Equal Weight	$73.00 ➝ $62.00
5/13/2025	HALO Halozyme Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
5/13/2025	HALO Halozyme Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Market Perform ➝ Underperform	$47.00
5/7/2025	HALO Halozyme Therapeutics	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/7/2025	HALO Halozyme Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$60.00 ➝ $65.00
5/5/2025	RGEN Repligen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$180.00 ➝ $180.00
5/2/2025	MDGL Madrigal Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$441.00 ➝ $458.00
5/2/2025	MDGL Madrigal Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$422.00 ➝ $460.00
5/2/2025	MDGL Madrigal Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$394.00 ➝ $420.00
4/30/2025	RGEN Repligen	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$202.00 ➝ $189.00

(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GHDX Genomic Health	$394.11M	6.05	$1.45 per share	43.76	$7.48 per share	8.48
HALO Halozyme Therapeutics	$1.08B	6.12	$4.36 per share	12.35	$2.95 per share	18.26
MDGL Madrigal Pharmaceuticals	$317.38M	19.93	N/A	N/A	$20.53 per share	13.88
RGEN Repligen	$650.43M	10.90	$2.35 per share	53.61	$35.19 per share	3.59

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GHDX Genomic Health	$25.68M	$1.05	60.42	36.88	N/A	12.81%	19.62%	14.89%	N/A
HALO Halozyme Therapeutics	$281.59M	$3.76	15.70	8.66	0.42	43.74%	157.78%	25.34%	8/5/2025 (Estimated)
MDGL Madrigal Pharmaceuticals	-$373.63M	-$18.05	N/A	N/A	N/A	N/A	-71.78%	-53.25%	8/6/2025 (Estimated)
RGEN Repligen	$35.60M	-$0.45	N/A	53.47	4.54	-4.64%	4.21%	2.94%	7/29/2025 (Estimated)

Latest GHDX, HALO, RGEN, and MDGL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/6/2025	Q1 2025	HALO Halozyme Therapeutics	$0.98	$1.11	+$0.13	$0.93	$231.21 million	$264.86 million
5/1/2025	Q1 2025	MDGL Madrigal Pharmaceuticals	-$3.62	-$3.32	+$0.30	-$3.32	$112.79 million	$137.25 million
4/29/2025	Q1 2025	RGEN Repligen	$0.35	$0.39	+$0.04	$0.10	$163.65 million	$169.17 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GHDX Genomic Health	N/A	N/A	N/A	N/A	N/A
HALO Halozyme Therapeutics	N/A	N/A	N/A	N/A	N/A
MDGL Madrigal Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RGEN Repligen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GHDX Genomic Health	0.15	5.96	5.96
HALO Halozyme Therapeutics	4.14	7.80	9.15
MDGL Madrigal Pharmaceuticals	0.15	5.98	5.93
RGEN Repligen	0.26	10.44	8.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GHDX Genomic Health	93.87%
HALO Halozyme Therapeutics	97.79%
MDGL Madrigal Pharmaceuticals	98.50%
RGEN Repligen	97.64%

Insider Ownership

Company	Insider Ownership
GHDX Genomic Health	31.30%
HALO Halozyme Therapeutics	2.40%
MDGL Madrigal Pharmaceuticals	21.50%
RGEN Repligen	1.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GHDX Genomic Health	829	37.59 million	N/A	Optionable
HALO Halozyme Therapeutics	390	123.22 million	120.20 million	Optionable
MDGL Madrigal Pharmaceuticals	90	22.20 million	16.84 million	Optionable
RGEN Repligen	2,020	56.18 million	55.36 million	Optionable

GHDX, HALO, RGEN, and MDGL Headlines

Recent News About These Companies

Repligen (NASDAQ:RGEN) Shares Down 3.1% - Should You Sell?

June 16 at 2:38 PM | marketbeat.com

Azzad Asset Management Inc. ADV Acquires Shares of 21,077 Repligen Co. (NASDAQ:RGEN)

June 15 at 5:18 AM | marketbeat.com

Repligen Co. (NASDAQ:RGEN) Receives $173.25 Average PT from Analysts

June 14 at 1:49 AM | americanbankingnews.com

Does Repligen Corp (RGEN) Have a Strong Pricing Power?

June 13 at 8:36 AM | insidermonkey.com

Repligen Co. (NASDAQ:RGEN) Receives Consensus Rating of "Moderate Buy" from Analysts

June 11, 2025 | marketbeat.com

Repligen: Long-Term Growth Gem Suffers Some Setbacks

June 8, 2025 | seekingalpha.com

Congress Asset Management Co. Grows Holdings in Repligen Co. (NASDAQ:RGEN)

June 8, 2025 | marketbeat.com

NBC Securities Inc. Purchases 2,672 Shares of Repligen Co. (NASDAQ:RGEN)

June 7, 2025 | marketbeat.com

GAMMA Investing LLC Has $15.51 Million Stock Position in Repligen Co. (NASDAQ:RGEN)

June 7, 2025 | marketbeat.com

Drug Development Inputs & Services Stocks Q1 In Review: Repligen (NASDAQ:RGEN) Vs Peers

June 5, 2025 | finance.yahoo.com

Craig-Hallum Sticks to Its Buy Rating for Repligen (RGEN)

June 5, 2025 | theglobeandmail.com

Winners And Losers Of Q1: Repligen (NASDAQ:RGEN) Vs The Rest Of The Drug Development Inputs & Services Stocks

June 5, 2025 | msn.com

Harbor Investment Advisory LLC Has $373,000 Stake in Repligen Co. (NASDAQ:RGEN)

June 4, 2025 | marketbeat.com

Repligen at William Blair Conference: Innovation Drives Growth

June 3, 2025 | investing.com

Repligen Co. (NASDAQ:RGEN) Stock Holdings Cut by Squarepoint Ops LLC

May 30, 2025 | marketbeat.com

Why Is Repligen (RGEN) Down 12.2% Since Last Earnings Report?

May 29, 2025 | zacks.com

Repligen Co. (NASDAQ:RGEN) Position Raised by Polar Asset Management Partners Inc.

May 29, 2025 | marketbeat.com

Tidal Investments LLC Decreases Position in Repligen Co. (NASDAQ:RGEN)

May 29, 2025 | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $33.88 Million Stock Position in Repligen Co. (NASDAQ:RGEN)

May 28, 2025 | marketbeat.com

Repligen Announces Publication of the Company’s 2024 Corporate Sustainability Report

May 27, 2025 | finance.yahoo.com

Repligen Announces Publication of the Company's 2024 Corporate Sustainability Report

May 27, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
Analysts Think These Stocks Could More Than Double in Value
By Nathan Reiff | May 23, 2025
View Analysts Think These Stocks Could More Than Double in Value
Intel’s Turnaround May Be the Best Bet No One’s Watching
By Jeffrey Neal Johnson | May 30, 2025
View Intel’s Turnaround May Be the Best Bet No One’s Watching
Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
By Thomas Hughes | May 27, 2025
View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
Meta's Institutional & Insider Data Fuels Bulls Despite Disparity
By Leo Miller | May 28, 2025
View Meta's Institutional & Insider Data Fuels Bulls Despite Disparity

GHDX, HALO, RGEN, and MDGL Company Descriptions

Genomic Health NASDAQ:GHDX

Genomic Health, Inc., a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions. It offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the breast cancer recurrence and chemotherapy benefit. The company also provides the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy; Oncotype DX prostate cancer test, which provides a genomic prostate score to predict disease aggressiveness in men with low risk prostate cancer, as well as to enhance treatment decisions for prostate cancer patients in conjunction with the Gleason score; and Oncotype DX AR-V7 nucleus detect tests for men with metastatic castration-resistant prostate cancer. In addition, it develops Oncoytpe DXi IVD breast recurrence score test; and Oncotype DX GPS test. The company offers its products through a network of distributors. Genomic Health, Inc. has license and development agreement with Biocartis N.V. to develop and commercialize an in vitro diagnostic of the Oncotype DX breast cancer test; collaboration agreement with Epic Sciences, Inc. to commercializeAR-V7 Nucleus Detect test; and license and development agreement with Cleveland Diagnostics, Inc. to develop and commercialize new prostate cancer tests. The company was founded in 2000 and is based in Redwood City, California.

Halozyme Therapeutics NASDAQ:HALO

$53.87 -0.11 (-0.20%)

As of 03:58 PM Eastern

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Madrigal Pharmaceuticals NASDAQ:MDGL

$284.87 -10.70 (-3.62%)

As of 03:58 PM Eastern

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

Repligen NASDAQ:RGEN

$126.19 -1.33 (-1.05%)

As of 03:58 PM Eastern

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time